Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
PLN 4.02
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'expens
Data is available to registered users only
Buy
Sell